CAS: 1876467-74-1

Elimusertib (BAY-1895344) is a potent, highly selective and orally available ATR inhibitor with an IC50 of 7 nM.Elimusertib shows potent anti-tumor efficacy in

(R)-3-Methyl-4-(4-(1-Methyl-1H-Pyrazol-5-Yl)-8-(1H-Pyrazol-3-Yl)-1,7-Naphthyridin-2-Yl)Morpholine

Elimusertib

BAY-1895344 is an inhibitor of the CDK4 and CDK6 proteins, which are tumor-promoting enzymes that regulate cell cycle progression. BAY-1895344 has been evaluated in clinical studies for the treatment of cancer with promising results. This drug was also shown to increase epidermal growth factor (EGF) levels in vitro and to promote autophagy, a process whereby cells degrade their own components. In addition, this compound has been shown to have a positive effect on telomere length and tumor response in patients with squamous carcinoma.

Applications BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor used in the treatment of advanced hyperproliferative disease, prophylaxis, solid tumors and lymphomas. References Wortmann, L., et al.: From PCT Int. Appl. (2016), WO 2016020320 A1 20160211